Prostate cancer is not breast cancer

Ajit Venniyoor

doi:10.4103/0971-5851.176980

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(01): 4-5
DOI: 10.4103/0971-5851.176980

REVIEW ARTICLE

Prostate cancer is not breast cancer

Authors

Ajit Venniyoor

Department of Medical Oncology, National Oncology Center, The Royal Hospital, Muscat, Sultanate of Oman

Abstract

PDF Download

Abstract

Cancers of the prostate and breast are hormone dependent cancers. There is a tendency to equate them and apply same algorithms for treatment. It is pointed out that metastatic prostate cancer with bone-only disease is a potentially fatal condition with a much poorer prognosis than metastatic breast cancer and needs a more aggressive approach.

Keywords

Bone-only disease - metastatic prostate cancer - prognosis

PDF (325 kb)

References

References
1 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489-502.
2 Valkenburg KC, Steensma MR, Williams BO, Zhong Z. Skeletal metastasis: Treatments, mouse models, and the Wnt signaling. Chin J Cancer 2013;32:380-96.
3 Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007). J Urol 2010;184:162-7.
4 Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer 2011;11:29.
5 Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
6 Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65:270-3.
7 Parker C, Nilsson S, Heinrich D, Helle SI, O′Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
8 Presented at ESMO; 2014. Available from: http://www.oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Genitourinary-Tumours-Prostate/Chemohormonal-therapy-versus-hormonal-therapy-for-hormone-naive-high-volume-newly-metastatic-prostate-cancer-PrCa-ECOG-led-phase-III-randomized-trial. [Last accessed on 2014 Dec 12].
9 Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14:149-58.